Form 4: BioMarin Director Robert J. Hombach Reports Acquisition of 4,720 Shares of Common Stock

Director Robert J. Hombach reported acquiring 4,720 shares of BioMarin Pharmaceutical Inc. common stock on May 21, 2024.

Summary

• Robert J. Hombach, a director of BioMarin Pharmaceutical Inc., filed a Form 4 with the SEC.
• The filing reports that Hombach acquired 4,720 shares of common stock on May 21, 2024, at a price of $0.
• Following the transaction, Hombach directly owns 35,220 shares of BioMarin common stock.
• The filing also includes a Power of Attorney, dated December 6, 2023, authorizing G. Eric Davis, Tae Sang Yoo, and Eric Fleekop to act on Hombach's behalf for Section 16 filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating an acquisition of shares by a director, which can be seen as a slightly positive sign of confidence, but it's not a major event.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.

Stakeholder Impact

• The acquisition of shares by a director may have a minor positive impact on shareholder sentiment.

Key Dates